Personalized medicine is a ubiquitous term that has come to be used to describe a medical model that proposes the customization of healthcare, such that decisions and/or treatments are tailored to each individual patient. Under this type of clinical practice model, diagnostic and prognostic decisions are often based upon selecting the most appropriate therapy based on a patient's genetic, demographic, and/or other pertinent information. The primary aim of this paper is to use a personalized medicine framework to better understand the relationship between neuropsychological testing and the progression of symptoms in a blast-induced mild Traumatic Brain Injury (mTBI) patient population. In this paper, we extended our earlier work on Constrained Spectral Partitioning (CSP), a graph-based approach that incorporates additional information from separate graphs to help improve the clustering quality on both graphs simultaneously. While our previous work demonstrated the effectiveness of this algorithm in its ability to accurately classify whether symptoms improved or declined over time, that work did not provide any insights into the progression of symptoms. Therefore, this paper sought to identify, from a clinical perspective, whether symptoms increased/decreased over time. To accomplish this, we developed a decision tree classifier to classify symptom progression based on the outputs from our CSP algorithm. We present results from four separate decision tree classifiers that illustrate the adaptability of these algorithms for utilization as decision rules for the treatment of patients following blast-induced mTBI. Decision tree classifier models are useful in the healthcare setting because patient health data (e.g., diagnosis of a condition or a type of treatment) can be imput into the model and, based on the health data variables, a resulting outcome can be suggested, and providers can use this outcome as information to direct their clinical treatment.
Introduction
Technological improvements over the past decade have paved the way for improved patient care across the healthcare spectrum. Medical personnel are more capable than ever of providing quality care in settings ranging from disaster response to emergency medicine. In the military medicine domain, however, practitioners have yet to receive the necessary training and resources to deal with the wide range of medical issues that arise on the battlefield. One such approach, which provides promise, is to focus on modeling and simulation (M&S) technologies that aim to individualize training and personalize medicine. Personalized medicine is a ubiquitous term that has come to be used to describe a medical model that proposes the customization of healthcare, such that decisions and/or treatments are tailored to each individual patient. 1 Under this type of clinical practice model, diagnostic and prognostic decisions are often based upon selecting the most appropriate therapy centered around the context of a patient's genetic, demographic, and any other relevant characteristics. 2 The primary aim of this paper is to use a personalized medicine framework model to better predict the underlying process behind the relationship between neuropsychological testing and the appearance of symptoms (both initially after the diagnosis of mild Traumatic Brain Injury (mTBI) and in the longer term) in a blastinduced mTBI population.
Blast-induced neurotrauma, and specifically mTBI, is a primary concern among veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF). [3] [4] [5] Much of the concern surrounding this injury has been the difficulty in establishing a universally accepted definition. 6 Research from our lab has focused on the use of Electronic Health Data (EHD) as a means for establishing more standardized criteria as they relate to a diagnosis of mTBI and other forms of neurotrauma. 7, 8 For example, we recently developed a graph theoretical model to predict an increase/decrease in symptomology based on medications prescribed prior to injury and neuropsychological testing conducted upon a patient's visit to a clinic after injury. 9 In this work, we showed that such a model can reliably outperform other parametrically and/or machine-learningbased models in terms of predicting patient outcomes.
In this paper, we wanted to extend our earlier work on Constrained Spectral Partitioning (CSP). [10] [11] [12] [13] [14] CSP attempts to incorporate additional (i.e., symptomology and/or medications) information from separate graphs to help improve the clustering quality on both graphs simultaneously. Here, clustering quality represents the extent to which an algorithm is able to accurately group similarly labeled data elements. For example, we previously sought to group patients on whether or not symptoms improve over time. We might incorporate information from one symptom graph (i.e., nausea) then to increase the clustering quality on another graph (i.e., dizziness).
In general, constrained clustering tries to incorporate Must-Link (ML) and Cannot-Link (CL) constraints into existing clustering algorithms. These ML constraints are used to cluster variables or instances that are related, or that are likely to be grouped into the same cluster. For example, if we were attempting to predict which instances would need to be present for a patient to be diagnosed with a disease, then a ML constraint might identify two common symptoms of the disease (e.g., headaches and dizziness for mTBI) and classify or cluster these two symptoms together. In contrast, a CL constraint functions in just the opposite manner and attempts to distinguish between two instances by identifying which instances or variables should not be clustered or grouped together.
In this paper, we sought to increase the clinical interpretability of our work. To accomplish this, we developed a decision tree classifier to classify symptom progression based on the outputs from our CSP algorithm. We show, more formally, how we can use a decision tree model to build a more personalized medicine framework for individual patients in order to better predict the appearance of symptoms. In this paper, we extend our earlier work on the use of CSP in the hopes of better understanding blastinduced mTBI. The focus of the current paper is not CSP, but rather to develop a further understanding of how the results from this algorithm could be used to better identify the associations between predictor variables and symptom progression. For a better understanding of CSP, the reader is referred to the Appendix.
While the focus of this paper was to develop a better clinical understanding for CSP, we first recognize the need to explain the use of graphs in a patient care setting. For a visual depiction of graphs, please see Figure 1 . Typically, graph-based analyses attempt to identify both symmetrical and asymmetrical relationships between discrete objects. A graph can be viewed as an abstract representation of a network consisting of nodes and a set of edges (or connections). An edge that connects two nodes suggests there is a relationship between both nodes in the graph and the weight of the edge indicates a measure of distance or similarity between the nodes. This weight might be represented using any number of measures, including the zero-order correlation between two nodes or the number of cooccurrences between events.
Formally, graphs can be represented as an adjacency matrix A. An edge that connects two nodes in a graph can then be represented in this adjacency matrix as Ai,j = 1. However, when no relationship exists between two nodes, then the entry in the adjacency matrix is identified as Ai,j = 0. The number of edges connecting to a particular node is described as the degree k. The edges in a network can be represented as either nondirectional, where the relationship between each node is homogenous, or directional, where the relationship between the nodes may be heterogeneous (one node influences the other).
Using CSP, we previously showed how a graph-based representation can be more effective in terms of classification accuracy for a small (sparsely labeled) dataset. 9 However, this work was limited in that the graph-based structure failed to identify how information propagates from one region of the graph (i.e., cluster of nodes) to another separate region. Therefore, in this paper we sought to extend our previous work by demonstrating the manner in which CSP classifies symptomology. To accomplish this, we developed a decision tree classifier and then examined the tree structure for several different symptomologies within our Concussion Restoration Care Center (CRCC) dataset.
Decision tree learning is one of the most widely used and practical methods for inductive inference and is used for approximating discrete-valued functions 15 ; however, due to cumbersomeness, they have recently stopped being as popular in clinical settings. Decision trees classify instances by sorting them down the ''tree'' beginning from a ''root'' to different ''branches'' and ''leaves'' in the dataset. This process allows for the classification of specific instances within the dataset. Each node in the tree acts as a test for each attribute for a particular instance.
We classified symptom changes (i.e., whether reported symptoms increased or decreased) from a group of blastinduced TBI patients. We argue here that the decision trees were constructed to assess how mTBI symptoms change over time. To foreshadow our methods, the decision trees were constructed such that we attempted to classify whether the various reported symptoms got better or worse over time. From a root node, the tree(s) descended into different (and most informative) branches corresponding to such issues as medications taken, neuropsychological assessments, and other pertinent variables from a patient's EHD. Branching of the trees was determined by those variables that provided the most information gain.
The paper is organized as follows: we begin with a description of the dataset in Section 2. Section 3 provides a primer of decision tree methodology and our construction of the tree. Section 4 discusses our empirical results. Finally, Section 5 provides some concluding remarks regarding how these methods might be applied to other M&S domains.
Data 2.1 Description of the dataset
Mild TBI is one of the most pervasive forms of neurotrauma that has affected military service members over the last decade. Indeed, mTBI is so common amongst OEF/OIF veterans that it has been labeled as the ''signature injury'' of these conflicts. 3 Unfortunately, very little research has been focused on trying to understand the relationship between reported symptomology following mTBI and data contained within the EHD. A primary goal within our research group has been to develop quantitative models of blast-induced mTBI. To accomplish this, we have focused on patients diagnosed with a blast-related mTBI and correlated health outcomes, including symptom progression, with a patient's EHD. For each patient in our dataset, EHD was examined to determine the medications that were initially prescribed prior to injury. For the purposes of this paper, we limited examination to medications prescribed prior to the patients' initial visit. In addition, we examined scores for each patient on the Automated Neuropsychological Assessment Metrics (ANAM) 4 TBI battery.
Data acquisition
We analyzed data obtained from the CRCC database, which contains symptomology, neurological assessment, and prescriptions of medications prescribed to military service members serving in Afghanistan from 2008 to 2012. Service members who potentially suffered a concussion in Afghanistan or a surrounding geographical area during the 2008-2012 observation period were referred to the CRCC for further evaluation.
This study was approved by the US Army Medical Research and Materiel Command Institutional Review Board, which granted a waiver of informed consent, and the Naval Medical Research Center. All data used in this study were collected in fulfillment with the regulations of the Institutional Review Board, de-identified for analysis, and used solely for this research.
Study population
Patients (N = 41) with a blast-related mTBI were analyzed for symptomology, prescribed medications, and neuropsychological testing. We defined blast-induced mTBI (concussion) as a traumatic brain injury exhibiting normal or common structural imaging patterns, Loss of Consciousness (LOC) of less than 30 minutes and/or Alteration of Consciousness (AOC), or Post-Traumatic Amnesia (PTA) lasting less than 24 hours.
Patients included in this analysis suffered neurotrauma (i.e., concussion) as a direct result of exposure to blast overpressure, often caused by an improvised explosive device (IED). The mechanism of mTBI injury was determined through a combination of a clinical interview and additional reports obtained through a medical record or supplementary records. If a record indicated the cause of injury was a motor vehicle accident or that it occurred during training with no blast, then the record was subsequently removed from the analysis. The current study did not differentiate whether the type of mTBI blast injury resulted from direct contact with a pressure blast or with an IED. No patients in our sample had penetrating brain injury or severe lacerations to the head, face, or neck.
Symptom reporting
A 16-item self-report questionnaire was presented by US enlisted medical personnel and was used to assess symptoms of mTBI. Approximately half of the 16 items were derived from the Military Acute Concussion Evaluation (MACE), and the other half were identified by clinicians as commonly reported problems specific to mTBI. Symptoms included headache, dizziness, visual changes, ringing in the ears, balance problems, nausea/vomiting, memory problems, trouble concentrating, irritability, sensitivity to light, hearing loss, fatigue/drowsiness, difficulty sleeping, confusion, trouble reading, and loss of temper. In addition, patients were asked to report any instances in the previous year in which they had sustained a blow to the head along with dizziness or LOC, with special attention to incidents occurring as a part of their military deployment. Patients were also asked to report the number of blast exposures they experienced that occurred within 50 meters of a blast epicenter. Similar injuries, such as a car accident or sports concussion, that occurred previous to the past year were also recorded. Patients with injuries within the last year that originated from anything other than blast exposures were excluded.
Computerized neurocognitive assessment
Patients diagnosed with mTBI were assessed using the ANAM version 4.0 TBI battery. 16 The ANAM-TBI is a collection of self-administered computerized neurocognitive assessments that assess different cognitive domains, such as visual search, spatial processing, and sustained attention. There are subtasks of the primary cognitive domains that include but are not limited to simple reaction time (SRT), procedural reaction time (PRO), mathematical processing (MTH), delayed matching to sample (M2S), code substitution learning (CDS), and code substitution delayed (CDD). The SRT task consists of the presentation of a stimulus (an asterisk sign, *) that the patient responds to by clicking a mouse button. The SRT task was presented at the beginning and end of the battery of tasks (SRT2 denotes the second instance of the SRT task). The PRO task involves a character (two, three, four, or five) presented on screen and the patient responds by clicking the left mouse button if a two or three is presented and then clicking the right mouse button if a four or five is presented. The MTH task presents basic arithmetic operations to which the patient indicates if the solution to the problem is greater than or less than five. The M2S task consists of the presentation of a 4 × 4 checkerboard image for two seconds and then, after a time interval, two checkerboards are presented, one of which matches the preceding checkerboard. The patient must indicate which checkerboard matched the one originally presented. The CDS task involves a string of nine digits paired with nine symbols, which remain at the top of the screen and then a pairing appears, for which the patient must indicate if the pairing is correct or incorrect. The CDD task is the delayed version of the CDS task and thus the symbols and digits do not remain at the top of the screen, but instead appear for a brief period and then the patient must select if a pairing is correct. For each task, the reaction time in milliseconds (ms), as well as the number of correct responses, is recorded. A throughput (TP) score is calculated using the reaction time and number of correct answers within a 1-minute time period to give an overall score.
Decision tree classifiers
From a practical perspective, decision trees operate via a recursive divide-and-conquer strategy (a graphical representation is provided in Figure 2 ). This process begins by first selecting an attribute to serve as the root node. Optimally, the root node would be a feature from the dataset that results in the purest outcome in terms of classification accuracy (i.e., whether the reported symptom increases or decreases). For example, if we chose the medication naproxen as the root node in our decision tree classifier, we would do so because the majority of patients that received the medication had a reduction in symptoms, while the majority of patients that did not receive naproxen did not report a change in symptoms (or the symptoms got Figure 2 . A graphical depiction of a standard decision tree. Decision trees descend via branching from a root node at the top layer to different attributes (aka leaves). worse). As the tree descends downward from the root node, different attributes are tested according to their corresponding values. This process was repeated, recursively, for each branch in the dataset. A stopping function was set if all instances within a layer have the same class, therein indicating that a pure layer had been reached with 100% accuracy.
A variety of different decision tree learning methods have been developed over the years. Generally speaking, however, decision tree learning is best suited for problems in which the instances are represented by attribute-value pairs and the target function has discrete output values. For the present paper, the attributes are defined by cut scores within the ANAM, and whether or not a specific medication was given to that patient.
Attribute selection
A core issue when building decision tree classifiers is to determine which attribute to test at each layer within the tree. Simply put, we sought to select the attribute that most clearly differentiated the two outputs of the model. For example, if we wanted to classify whether dizziness was likely to increase or decrease in a patient, we may look at a particular medication or performance on ANAM. The most principled method for attribute selection was to measure information gain. Here, we applied entropy to measure information gain. Given a collection S, containing both positive and negative examples of the target outcome, the entropy of S relative to classification is defined as follows:
As can be seen from the equation above, we needed only to sum p i log 2 p i for all cases. Because probabilities are always less than 1 and logarithms are negative if the value is less than 1 (which probabilities always are), we multiply each value by a negative, creating a positive entropy value. Here, p i is the proportion of S belonging to class i. The target attribute can take on n possible values, so entropy can be as large as log 2 n.
Tree selection
As discussed previously, we examined a total of 16 different symptoms assessed through the MACE questionnaire. For a subset of these symptoms, very few participants exhibited a decrease in symptomology over time. Indeed, in some cases, as few as two patients reported a reduction of symptoms over the observation period. To avoid overfitting of our data, we restricted our search to those cases in which at least 20% of the observed cases reported a decrease in symptoms. Using these criteria, decision trees were constructed from the following symptoms: balance, concentration, headache, sensitivity to light, irritability, and difficulty sleeping. However, for two of these trees (balance and difficulty sleeping) the decision trees were uninformative, with no positive entropy for nodes. Therefore, we focused our analysis and interpretation of results on the remaining symptoms.
Experimental results

Concentration
The results from the Concentration Decision Tree are illustrated in Figure 3 . Based on the information gain from the observed attributes, the root node for the Concentration Decision Tree was whether the patient was taking Phenergan. Phenergan is a commonly prescribed medication for nausea, suggesting that taking this medication prior to blast-induced mTBI may help to alleviate symptoms over and above what might be seen from normal reduction of symptoms. The next branch of the Concentration Decision Tree was whether the individual was also prescribed Fioricet (prior to injury), a medication commonly prescribed to help alleviate pain. Two remaining branches exist for the Concentration Decision Tree: naproxen and amitriptyline, respectively. Naproxen is a commonly prescribed anti-inflammatory while amitriptyline is an antidepressant.
Headache
As shown in Figure 4 , the results from the Headache Decision Tree stand in stark contrast to Concentration. Specifically, the root node for the Headache Decision Tree was performance on the Matching-to-Sample test of the ANAM test battery. However, the next three branches of this tree were medications: acetaminophen, oxycodone, and zolpidem, respectively. These medications, while having a variety of clinical utility, are generally prescribed for pain relief (acetaminophen and oxycodone) and sleep disturbance (zolpidem). The final two branches of this decision are again focused on performance of the ANAM: CDD and Matching-to Sample. These findings may be important as they potentially implicate that, unlike concentration, headache symptoms may be a combination of both physiological and cognitive factors.
Sensitivity to light
As show in Figure 5 , the results from the Sensitivity to Light Decision Tree were more diverse in attributes that influenced resulting branches. Specifically, the root node for this Decision Tree was the medication zolpidem. However, two major branches existed at the second layer of the tree, with both focusing on performance within ANAM. For those individuals prescribed zolpidem, the next major factor in determining symptom progression was performance on the PRO task. However, for individuals not prescribed zolpidem, performance on MTH provided more information gain.
Irritability
Symptom progression for Irritability was influenced more by prescribed medications than ANAM performance. As shown in Figure 6 , the root node for the Irritability Decision Tree was the medication Flexeril, a prescribed muscle relaxant. The decision tree was fairly stable at predicting symptom outcome for patients not prescribed Flexeril. However, for those individuals prescribed this medication, two further branches were discovered in the tree: Fioricet and naproxen.
Conclusions and discussion
The primary aim of this paper was to define the relationships that exist between symptom progression and data contained within a patient's EHD, including performance on neuropsychological testing (i.e., ANAM) as well as prescribed medications. Here, we demonstrated that for some symptoms, such as Concentration and Irritability, the reduction of symptoms was almost entirely dependent upon medications taken prior to injury. When examining the concentration decision tree, we found that the drugs Phenergan (anti-nausea), Fioricet (pain reliever), naproxen (anti-inflammatory), and amitriptyline (anti-depressant) were important for predicting changes in concentration. Prior studies have examined the effect of naproxen-related compounds on brain function, and these studies are consistent in finding that naproxen may act to attenuate the edema and cell death associated with TBI. 17 In addition, we might infer that alleviating inflammation and physical distractions, such as nausea and pain, would allow a patient to better concentrate on a task. In the related decision tree examining Headache, we found that the drugs acetaminophen (pain reliever), oxycodone (pain reliever), and zolpidem (sleep aid) were influential for headaches. It follows that reducing the overall pain and improving the restorative sleep of a patient with mTBI will improve their overall health and, thus, may reduce Headache. Previous studies have confirmed that sleep is an important factor in overall satisfaction with life in rehabilitation in service members. 18 Likewise, we observed that sleep may be a critical factor when examining Sensitivity to Light in which we found that the drug zolpidem (sleep aid) was important for Concentration, which has also been observed in veteran populations recovering from mTBI injuries, and may be related to TBI and post-traumatic stress disorder (PTSD) symptoms. 19 Finally, when examining the Irritability Decision Tree, the drugs Flexeril (muscle relaxant), Fioricet (pain reliever), and naproxen (anti-inflammatory) were influential for irritability. Once more we see that reducing pain and global inflammation may be important for improving mood and overall good feeling. This is consistent with the observation that individuals who suffer from chronic pain may find themselves more easily irritated. 19 However, in other cases, it was clear that neuropsychological tests are much better at predicting whether blast-induced mTBI symptoms would decrease over time.
We believe that this paper on decision tree analysis demonstrates an early prototype for using informatics to improve medical decision making. Decision trees continue to provide both a practical and intuitive manner to understanding the decision process, and may in the future be beneficial in a combat clinical setting. Others have shown that the use of similar methodologies can be quite informative across clinical settings. 21, 22 In addition, it may follow that this type of analysis may help to inform research methods in determining critical decision points and instruct analysis plans when working with large patient record datasets. 22 It should be noted that the data that was reported in this paper is only a subset of a larger pool of EHD from service members returning from theater. As the relationship between how neurocognitive performance may affect symptom progression after a mTBI becomes clearer, we can gather more information and better optimize the research methods used to analyze these records.
where the volume is the sum of all affinities vol(A) = P i, j A i, j . The relaxed problem has the following objective (for a two-way partition):
where the normalized Laplacian can be defined as L = D À 1 2 LD À 1 2 . Previously, we applied a clustering approach to graphs in a transductive setting. 14 Consider a graph where each instance is a patient; we could then apply CSP such that the graph edges only use a subset of the features (i.e., medication taken, results of test, etc.). Then, the graph can then be cut such that for each sub-graph we generate a set of associated predictions.
Our algorithm encodes user supervision as an N × N constraint matrix Q. In traditional constrained clustering, ML and CL constraints are used such that ML constraints are generated between similarly labeled points and CL constraints are generated between differently labeled points. Previously, we showed that these constraints can be naturally encoded as follows:
Then, if we let u ∈ { − 1, + 1}, and N be a cluster indicator vector, then u i = + 1 if node i belongs to cluster + and u i = − 1 if node i belongs to cluster − . From this we can show the following:
will be a measure of how well the constraints in Q are satisfied by the cluster assignment in u: the measure will increase by 1 if Q ij = 1 and nodes i and j have the same sign in u; the measure will decrease by 1 if (1) Q ij = 1 but nodes i and j have different signs in u, or (2) Q ij = − 1 but nodes i and j have the same sign in u. To accommodate degree-of-belief constraints, we simultaneously relax the cluster indicator vector u and the constraint matrix Q such that:
Q ij is positive if we believe nodes i and j belong to the same class; Q ij is negative if we believe nodes i and j belong to different classes; the magnitude of Q ij indicates how strong the belief is.
Consequently, u T Qu becomes a real-valued measure of how well the constraints in Q have been satisfied, in the relaxed sense. For example, Q ij < 0 means we believe nodes i and j belong to different classes, then in order to improve u T Qu, we should assign u i and u j with values of different signs; similarly, Q ij > 0 means nodes i and j are believed to belong to the same class, then we should assign u i and u j with values of the same sign. The larger u T Qu is, the better the cluster assignment u conforms to the given constraints in Q. Now, given this real-valued measure, rather than trying to satisfy all the constraints given in Q, we can lowerbound this measure with a constant a ∈ R:
By substituting u by D À 1 2 v above, the inequality becomes
is the normalized constraint matrix. We append this lowerbound constraint to the objective function of unconstrained spectral clustering and we have Problem 1 (Constrained Spectral Clustering). Given a normalized graph Laplacian L, a normalized constraint matrix Q, and a threshold, we want to optimize the following objective function: Here, v T Lv is the cost of the cut, which is to minimize; the first constraint v T Qv ≥ a is to lower-bound how well the constraints in Q are satisfied; the second constraint v T v = vol G ð Þ normalizes v; the third constraint v 6 ¼ D 1 2 1 rules out the trivial solution D 1 2 1. Suppose v* is the optimal solution, then u * = D À 1 2 v * is the optimal cluster indicator vector. It is easy to see that unconstrained spectral clustering can be covered as a special case of our formulation where Q = I and = vol(G). 
